Given the potential of emerging advanced therapies, market demand is likely to continue to grow. Generating the required quantity of cells efficiently becomes even more challenging when the cells of interest are attachment-dependent, such as induced pluripotent stem cells (iPSCs). The choice of cell culture platform will have significant operational and commercial impacts.
This guide explores what researchers should consider when creating a risk-mitigating adherent culture process for cell and gene therapy scale-up.
Thank you for requesting our whitepaper. Please click on the link below to download your copy.
A copy will also be sent to the email address you submitted on the form.